Arcellx Raises $115m To Advance Novel T-Cell Therapies
First CAR-T In Phase I, Second Construct Heading For Clinic
The company’s first candidate is a BCMA-targeting CAR-T, but Arcellx also is developing ARC T-cells controlled by a synthetic protein. Both have a binding domain that may confer better safety and efficacy than competitors.
